A Study Comparing Cemiplimab-based Treatments for Adult Participants With Locally Advanced Basal Cell Skin Cancer (laBCC)

Key Inclusion Criteria:

• Histologic confirmation of BCC by local board-certified pathologist, as described in the protocol
• At least one lesion that is measurable by study criteria, defined as ≥ 1cm in at least one dimension, as assessed by radiology and/or digital medical photography, as described in the protocol
• The treating physician must document that the participant is not appropriate for curative-intent surgery or curative-intent radiation
• The treating physician must document that the participant does not wish to receive a hedgehog pathway inhibitor (HHI) or is not a candidate for an HHI
• Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1

Subsequent Therapy Arm - specific inclusion criteria:

• Documentation of histopathologic diagnosis of basal cell carcinoma - NOT necessary
• Submission of tumor or blood for exploratory correlative research - NOT necessary

Key Exclusion Criteria:

• Metastatic disease to lymph node(s) or distant site(s) (Note: involvement of lymph node due to direct invasion from overlying cutaneous BCC is still considered laBCC, and is not excluded)
• History or current evidence of significant cardiovascular disease, as described in the protocol
• Exposure to any prior systemic therapy (eg, HHI or an immune checkpoint inhibitor) or locally injectable agent for laBCC, as described in the protocol
• Current participation OR past participation in another investigational trial in which an investigational intervention (eg, drug, vaccine, invasive device) was administered within 4 weeks before planned first dose of study intervention in this clinical trial.

Subsequent Therapy Arm - specific exclusion criteria:

• Receipt of any anti-cancer therapy (including HHIs, radiation, surgery, or other systemic therapy) for BCC, AFTER treatment on Arms A, B, or C.

NOTE: Other protocol defined inclusion/exclusion criteria apply